Bleakley Financial Group LLC bought a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 32,628 shares of the company’s stock, valued at approximately $81,000. Bleakley Financial Group LLC owned approximately 0.06% of Ventyx Biosciences as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in the business. Legal & General Group Plc boosted its position in Ventyx Biosciences by 152.3% in the second quarter. Legal & General Group Plc now owns 2,422 shares of the company’s stock valued at $30,000 after buying an additional 1,462 shares in the last quarter. UBS Group AG acquired a new position in Ventyx Biosciences in the fourth quarter valued at about $40,000. China Universal Asset Management Co. Ltd. boosted its position in Ventyx Biosciences by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,506 shares of the company’s stock valued at $52,000 after buying an additional 739 shares in the last quarter. SG Americas Securities LLC boosted its position in Ventyx Biosciences by 61.4% in the fourth quarter. SG Americas Securities LLC now owns 37,261 shares of the company’s stock valued at $92,000 after buying an additional 14,177 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its position in Ventyx Biosciences by 93.7% in the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the company’s stock valued at $127,000 after buying an additional 1,870 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors and hedge funds.
Ventyx Biosciences Price Performance
VTYX opened at $4.76 on Wednesday. The company has a market cap of $335.58 million, a price-to-earnings ratio of -1.44 and a beta of 0.27. The firm has a 50 day simple moving average of $5.80 and a 200 day simple moving average of $6.71. Ventyx Biosciences, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $40.58.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. Lifesci Capital upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 28th. Wells Fargo & Company upgraded shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $7.00 to $16.00 in a research report on Tuesday, March 12th. Oppenheimer upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Tuesday, March 12th. Finally, Canaccord Genuity Group reduced their target price on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Ventyx Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.
View Our Latest Report on VTYX
Ventyx Biosciences Company Profile
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Further Reading
- Five stocks we like better than Ventyx Biosciences
- 5 Top Rated Dividend Stocks to Consider
- Silicon Motion Proves That AI in Motion Stays in Motion
- How Technical Indicators Can Help You Find Oversold Stocks
- Undervalued UnitedHealth Group Won’t Be For Long
- What is the S&P 500 and How It is Distinct from Other Indexes
- The 5 Stocks Most Sold By Insiders This Year
Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report).
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.